Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Neuroendocrine Tumors 102Carcinoid Tumor 22Neoplasms 16Neoplasm Metastasis 10Gastro-enteropancreatic neuroendocrine tumor 10Carcinoma, Neuroendocrine 9Adenoma, Islet Cell 9Pancreatic Neoplasms 7Carcinoma 7Pheochromocytoma 6Paraganglioma 6Neuroblastoma 6Colorectal Neoplasms 6Carcinoma, Islet Cell 6Somatostatinoma 5Gastrointestinal Neoplasms 5Vipoma 4Small Cell Lung Carcinoma 4Serotonin Syndrome 4Neuroectodermal Tumors, Primitive 4Melanoma 4Medulloblastoma 4Lung Neoplasms 4Intestinal Neoplasms 4Gastrinoma 4Carcinoma, Non-Small-Cell Lung 4Adenocarcinoma 4Prostatic Neoplasms 3Neuroectodermal Tumors 3Neoplasms, Nerve Tissue 3

Interventions

lanreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Flushing × NET × Clear all
NCT00774930 2022-10-14

ELECT

Ipsen

Phase 3 Completed
115 enrolled 17 charts
EndocrineNET

Carcinoid Tumor, Diarrhea, Flushing, Neuroendocrine Tumors, Serotonin Syndrome

NCT01886287 2015-01-12

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
2 enrolled 4 charts
EndocrineNET

Diarrhea, Flushing, Neoplasm Metastasis, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡